• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
Twitter Youtube Facebook Linkedin Instagram
RESILIENCEH2020

RESILIENCE Proyect

A European Commission-funded project aimed at reducing the incidence of heart failure in cancer survivors

Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure.

RESILIENCE Project tests a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages.

RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.

More
Healthy Heart
Healthy-Heart
Vulnerable Heart
Vulnerable-Heart
Heart Failure
Heart-Failure

RESILIENCE PROJECT NEWS

October 24 2023

Science and Innovation Week

On Thursday, November 16th at 19:00 hours we will organize the “RESILIENCE Workshop and laboratory visit. Surviving cancer with…

THE CHALLENGE:
Reduce the Heart Failure in Cancer Survivors

Thanks to the great scientific and medical advances, the prevalence of cancer survivors in increasing in Europe. However, cancer survivors are at high risk for cardiovascular complications. Among them, heart failure is especially worrisome. There is a strong need to reduce the burden of disability in cancer survivors and to increase their quality of life.

More

THE THERAPY:
Remote Ischemic Conditioning

Remote Ischemic Conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.

More

CARDIAC MAGNETIC RESONANCE

Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

More

CLINICAL TRIAL SYNOPSIS

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.

More
  • Patients at risk for cardiotoxicity
  • Remote ischemic conditioning vs. Sham
  • Three CMR studies

WHY LYMPHOMA

Lymphoma treatment includes the use of anthracyclines within a homogeneous combination chemotherapy. Lymphomas are specially vulnerable to anthracycline-induced heart failure. Lymphoma affects similarly women and men, and it it thus ideal to study gender differences in cardiotoxicity.

More

For Scientist

Read the most recent scientific advances in the field by RESILIENCE partners.

Go to Section

For General Public

Read the most recent newsletters, press releases, and other information about RESILIENCE in layperson´s language.

Go to Section

For Patients

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

Use our Form

Partners

Subscribe to our Newsletter

Resilience

Cardiac Magnetic Resonance

  • Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

Clinical Trial Synopsis

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischemic Conditioning.

For patients

Legals

Follow Us

Twitter Youtube Facebook Linkedin Instagram
  • This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions